TCR2 Therapeutics IncTCRR has announced topline results from the Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors.
Gavo-cel demonstrated a disease control rate (DCR) of 77%. 28 of the 30 (93%) patients evaluable for efficacy experienced tumor regression of their target lesions, ranging in magnitude from 4% to 80%.
Eight patients experienced target lesion regression greater than 30%, six of whom achieved a partial response (PR).
One patient with cholangiocarcinoma was also considered to have achieved a PR, demonstrating that gavo-cel has induced responses in every tumor type tested.
The overall response rate (ORR) among patients who received gavo-cel following lymphodepletion chemotherapy was 22% by BICR and 26% by investigator assessment.
The median overall survival (OS) for patients with MPM was 11.2 months, whereas the median progression-free survival (PFS) for patients with MPM was 5.6 months.
Gavo-cel was generally well tolerated, with a manageable adverse event profile up to DL5.
Price Action: TCRR shares are up 9.47% at $1.85 during the premarket session on the last check Wednesday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
